BharatNotes What is mRNA Vaccine?
An mRNA (messenger RNA) vaccine works by giving the body's own cells a temporary set of genetic instructions. Instead of injecting a weakened or inactivated pathogen — as traditional vaccines do — it delivers a strand of synthetic mRNA that codes for a single, harmless protein fragment of the target pathogen, most famously the spike (S) protein of the SARS-CoV-2 virus. The cell reads these instructions, builds the protein, displays it to the immune system, and then destroys the mRNA. Crucially, the mRNA never enters the cell nucleus and does not integrate into or alter human DNA.
How It Works
The fragile mRNA is packaged inside a lipid nanoparticle (LNP) — a microscopic protective bubble of fat. The LNP shields the mRNA from degradation and helps it enter cells. Two lipid components are central: an ionizable lipid (positively charged at low pH to bind the RNA, neutral at physiological pH to reduce toxicity) and a PEGylated lipid (which prolongs circulation by limiting clearance). Once inside, ribosomes translate the mRNA into the spike protein, which is presented as an antigen, triggering antibody and memory-cell responses.
A key scientific hurdle — that foreign mRNA provokes harmful inflammation — was solved by Katalin Karikó and Drew Weissman, who showed in 2005 that modifying RNA's nucleoside bases suppressed this response and boosted protein output. They were awarded the 2023 Nobel Prize in Physiology or Medicine for this work.
Global and Indian Milestones
| Vaccine | Developer | First authorisation |
|---|---|---|
| Comirnaty | Pfizer-BioNTech | UK 2-Dec-2020; US FDA EUA 11-Dec-2020 |
| Spikevax | Moderna | US FDA EUA 18-Dec-2020 |
| GEMCOVAC-19 | Gennova (India) | DCGI EUA, June 2022 |
| GEMCOVAC-OM | Gennova (India) | DCGI EUA, 19-Jun-2023 |
GEMCOVAC-19 was India's first indigenous mRNA vaccine and reportedly the world's third mRNA COVID-19 vaccine to be approved. Its successor, GEMCOVAC-OM, is an Omicron-specific booster launched by Union Minister Dr Jitendra Singh (PIB, June 2023). Notably, GEMCOVAC-OM is thermostable — it does not need the ultra-cold-chain storage required by early mRNA vaccines — and is given intradermally using a needle-free device. It was the fifth vaccine supported under Mission COVID Suraksha (DBT-BIRAC, Atmanirbhar Bharat 3.0).
Significance
mRNA technology is a programmable platform: changing the genetic sequence can retarget the vaccine to new variants or entirely new diseases within weeks, making it faster than conventional vaccine manufacturing. Research now extends to influenza, RSV, HIV and personalised cancer vaccines. For India, indigenous mRNA capability reduces import dependence and strengthens biosecurity.
UPSC Angle
For Prelims, focus on the mechanism (no live virus, no DNA alteration, role of LNPs) and Indian firsts (GEMCOVAC). For Mains GS3, situate it within indigenisation of technology, public-health preparedness and the DBT-BIRAC innovation ecosystem. This is a foundational concept underpinning the wider biotechnology and vaccine-platform topic family.
